Out-licensing
- Out-licensing
- View
Inno-C08001 (Carvedilol CR)
Full description
Inno-C08001 is indicated for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction. The active ingredient of Inno-C08001 is poorly soluble, especially in aqueous medium, which can limit the release and absorption of the drug in the gastrointestinal tract. Its immediate release formulation is given twice daily. Inno-C08001 is designed to enhance the solubility, and as an extended-release tablet, it is intended for once-daily administration.
Development status
Type of business relationship sought
Type of business relationship is open for discussion.
Related reports
Licensing contact
Company details
INNOPHARMAX is a specialty pharmaceutical company focused in the treatment of infectious diseases,immunology and oncology via DDS technology to improve safety & effectivene of currently available drug
View profileRelated technologies
- Treatment and Diagnosis of Cancer, Diabetes and Other Disorders Using Adrenomedullin Peptides and Antibodies
- Esmolol 2500 mg/10ml ampoule
- Active Guidewire Visualization Device and System for MRI Guided Interventions
- Novel Composition and Methods for Regulation of Smooth Muscle Cells and Blood Pressure by expression of specific Ca2+-activated K+ Channels (BK Channels) (07-40)
- 3D Biomatrix - Three dimensional (3D) cell culture technology
Related categories
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us